Article ; Online: In Silico Study towards Repositioning of FDA-Approved Drug Candidates for Anticoronaviral Therapy: Molecular Docking, Molecular Dynamics and Binding Free Energy Calculations.
Molecules (Basel, Switzerland)
2022 Volume 27, Issue 18
Abstract: The SARS-CoV-2 targets were evaluated for a set of FDA-approved drugs using a combination of drug repositioning and rigorous computational modeling methodologies such as molecular docking and molecular dynamics (MD) simulations followed by binding free ... ...
Abstract | The SARS-CoV-2 targets were evaluated for a set of FDA-approved drugs using a combination of drug repositioning and rigorous computational modeling methodologies such as molecular docking and molecular dynamics (MD) simulations followed by binding free energy calculations. Six FDA-approved drugs including, Ouabain, Digitoxin, Digoxin, Proscillaridin, Salinomycin and Niclosamide with promising anti-SARS-CoV-2 activity were screened in silico against four SARS-CoV-2 proteins-papain-like protease (PLpro), RNA-dependent RNA polymerase (RdRp), SARS-CoV-2 main protease (Mpro), and adaptor-associated kinase 1 (AAK1)-in an attempt to define their promising targets. The applied computational techniques suggest that all the tested drugs exhibited excellent binding patterns with higher scores and stable complexes compared to the native protein cocrystallized inhibitors. Ouabain was suggested to act as a dual inhibitor for both PLpro and Mpro enzymes, while Digitoxin bonded perfectly to RdRp. In addition, Salinomycin targeted PLpro. Particularly, Niclosamide was found to target AAK1 with greater affinity compared to the reference drug. Our study provides comprehensive molecular-level insights for identifying or designing novel anti-COVID-19 drugs. |
---|---|
MeSH term(s) | Antiviral Agents/chemistry ; COVID-19 ; Cysteine Endopeptidases/chemistry ; Digitoxin ; Digoxin ; Drug Repositioning ; Humans ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Niclosamide ; Ouabain ; Papain/metabolism ; Proscillaridin ; RNA-Dependent RNA Polymerase ; SARS-CoV-2 |
Chemical Substances | Antiviral Agents ; Ouabain (5ACL011P69) ; Digoxin (73K4184T59) ; Niclosamide (8KK8CQ2K8G) ; Digitoxin (E90NZP2L9U) ; RNA-Dependent RNA Polymerase (EC 2.7.7.48) ; Cysteine Endopeptidases (EC 3.4.22.-) ; Papain (EC 3.4.22.2) ; Proscillaridin (KC6BL281EN) |
Language | English |
Publishing date | 2022-09-14 |
Publishing country | Switzerland |
Document type | Journal Article |
ZDB-ID | 1413402-0 |
ISSN | 1420-3049 ; 1431-5165 ; 1420-3049 |
ISSN (online) | 1420-3049 |
ISSN | 1431-5165 ; 1420-3049 |
DOI | 10.3390/molecules27185988 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.MO 81: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.